SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer-Reference-Cited by-同舟云学术

SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer

Published:2018-09-20 Issue:1 Volume:37 Page:95-105
ISSN:0724-4983
Container-title:World Journal of Urology
language:en
Short-container-title:World J Urol

Author:

Merseburger Axel S.,Apolo Andrea B.,Chowdhury Simon,Hahn Noah M.,Galsky Matthew D.,Milowsky Matthew I.,Petrylak Daniel,Powles Tom,Quinn David I.,Rosenberg Jonathan E.,Siefker-Radtke Arlene,Sonpavde Guru,Sternberg Cora N.

Publisher

Springer Science and Business Media LLC

Subject

Urology

Link

http://link.springer.com/article/10.1007/s00345-018-2486-1/fulltext.html

Reference63 articles.

1. Sternberg CN, Yagoda A, Scher HI et al (1989) Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 64:2448–2458

2. Loehrer PJ Sr, Einhorn LH, Elson PJ et al (1992) A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 10:1066–1073

3. von der Maase H, Hansen SW, Roberts JT et al (2000) Gemcitabine and cisplatin vs. methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068–3077

4. Sternberg CN, de Mulder PH, Schornagel JH et al (2001) Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor vs. classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 19:2638–2646

5. McConkey DCW, Shen Y, Lee I, Porten S, Matin S, Kamat A, Corn P, Millikan R, Dinney C, Czerniak B, Siefker-Radtke A (2016) A prognostic gene expression signature in the molecular classification of chemotherapy-naive urothelial cancer is predictive of clinical outcomes from neoadjuvant chemotherapy: a phase 2 trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with bevacizumab in urothelial cancer. Eur Eurol 69:855–862

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enfortumab vedotin as a salvage option as 5th line therapy for metastatic urothelial bladder cancer;Aktuelle Urologie;2023-11-14

2. Avelumab as First-Line Maintenance Treatment in Locally Advanced or Metastatic Urothelial Carcinoma;Advances in Therapy;2023-08-22

3. A reporting quality evaluation of the clinical practice guidelines for bladder cancer based on the RIGHT checklist;Translational Andrology and Urology;2022-11

4. Profiling of extracellular vesicles of metastatic urothelial cancer patients to discover protein signatures related to treatment outcome;Molecular Oncology;2022-08-12

5. Imaging features of primary mucinous adenocarcinoma of bladder outlet and urethra: a case report and literature review;Translational Cancer Research;2022-07